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ABSTRACT 
Background-Fine needle aspiration cytology (FNAC) and Liquid based 
cytology(LBC) are minimally traumatic  techniques used in the pre-operative 
diagnosis of lesions of breast. They can be used to determine ER,PR and Her-2/neu 
during the pre-operative period. Aim of study - To compare the cytomorphological 
features of conventional FNAC and Liquid Based Cytology and to evaluate the  role 
of these techniques in the diagnosis as well as in the determination of prognostic and 
predictive factors. Materials and methods-30 cases of FNAC proven malignant 
lesions of breast were chosen and the cytomorphological features of conventional 
FNAC were compared with that of Liquid based cytology smears prepared using U-
Prep and Nanocyt technology. ER,PR and Her-2/neu was performed on conventional 
FNAC and LBC smears and the diagnostic and prognostic value of these techniques 
were evaluated. Results-The LBC was found to be better in terms of cellularity, clear 
background and monolayers while the cell architecture and the cytoplasmic and 
nuclear details were better preserved in conventional FNAC. Immunocytochemistry 
on FNAC was found to be very effective in predicting the response of the breast 
cancer to neoadjuvant chemo or hormone therapy and to determine prognosis. 
Immunocytochemistry on LBC was not found to be as effective as in conventional 
smears. The intensity of staining was found to be very poor. Conclusion-
Conventional FNAC and LBC, though they have their own merits and demerits, they 
have comparable diagnostic accuracy and a combination of these methods have 
superior diagnostic value. Immunocytochemistry on conventional FNAC is an 
effective tool to evaluate the prognostic and predictive factors of breast during the pre-
operative period while immunocytochemistry on LBC is not as effective as in LBC. 
Key words-Fine needle aspiration cytology, Liquid based cytology, Neoadjuvant 
chemotherapy 
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INTRODUCTION 
 
Breast carcinoma is an important cancer affecting women in the 
industrialized world. Breast cancer is a serious public health issue at present. 
Breast carcinoma ranks second among prevalence of cancers in women in India1. 
It is estimated that 7% of global burden of breast cancer is borne by India. 
Breast cancer constitutes one fifths of cancer among women in India1.The number 
of  deaths in India due to breast cancer is around 50,000 annually1. The history of 
breast cancer in close relatives is a very important risk factor. The mutations of 
the breast cancer genes BRCA1 and BRCA2 is another common risk factor seen in 
carcinoma breast2. 
FNAC has been accepted by WHO as an important technique in the 
evaluation of breast cancer3.It  is a safe, cost-effective, minimally traumatic  
technique  for rapid and accurate diagnosis  of  breast  lesions . The efforts to 
develop specific and scientific methods has led to liquid-based cytology 
preparation technique. The factors which help LBC to excel routine FNAC are 
enhanced fixation, paucity of background blood debris, and complete cell transfer. 
Another added advantage of  LBC is that the  residual material in the fixative can 
be used for pre-operative determination of ER,PR and Her-2/neu in breast cancer4. 
There have been only few studies to compare and analyse the 
cytomorphological features of breast aspirates in conventional smears and liquid 
based preparations. Also, only a few studies focus on comparison of results of 
immunocytochemistry in conventional smears and liquid based preparations. Thus 
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this study was conducted to evaluate the use of conventional FNAC and LBC  in 
pre-operative diagnosis as well as prognosis of breast malignancies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
AIMS AND OBJECTIVES 
 
1. To study the cytomorphology of breast cancer in conventional FNAC and 
LBC. 
2. To study  ER, PR and Her-2/neu status of breast malignancy in 
conventional FNAC and liquid based cytology. 
3. To evaluate the diagnostic and prognostic value of conventional smears Vs 
liquid based cytology. 
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REVIEW OF LITERATURE 
 
History 
It was more than 3,500 years ago that the Ancient Egyptians first identified 
breast cancer. Cancer was first defined in Egypt at around 1600 BC. Hippocrates 
described breast cancer as a humoral disease in 460 B.C. The Edwin Smith 
Papyrus was the one to describe 8 cases of tumors of breast that were treated by 
cauterization.5 
In 1757 Henri Le Dran, a French physician proposed that  breast cancer can 
be treated by surgical removal of the tumor along with infected lymph nodes of 
the armpits .This was also supported by  Claude-Nicolas Le Cat. 6 
Embryology of breast                            
           At the  fifth  week  of  gestation, the  mammary  glands  arise from  the  
ectodermal  mammary ridges. These ridges  extend  on  the  ventral  surface  of   
the  fetus  from  the  axillary  to  inguinal  region bilaterally.However,major part 
of mammary ridge disappear at about seventh week7, 8, 9. 
            The small  portion  of  mammary ridge in the  fourth  or  fifth  intercostals  
space  that persist are referred to as primary mammary  buds . The  underlying 
mesoderm  is penetrated by the primary  buds  of  ectoderm.Mammary lobules are 
formed from the primary  mammary  buds that develop into  secondary  buds  by  
12th week  of  gestation10.  
The  ectodermal  penetration which occurs during  fifth month  in  utero 
produce   15 –20 radial branching ingrowths  into  the  developing  breast. The  
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lactiferous  ducts  and  their  branches are formed from small  lumina  which  
develop within  the mammary  buds . The lactiferous  ducts  converge  to  open   
into  a    mammary  pit ,  that later   transforms  into  nipple  during  infancy.7,8 
Anatomy  
Skin and subcutaneous tissue overlie the breast.Breast rests on the pectoral 
muscle separated by a fascia. The vertical extension of breast is from 2nd to 6th rib 
and the  horizontal extension is from the outer border of sternum to the mid 
axillary line.The axillary tail of spence is a small extension  that extends laterally 
towards the axilla11. 
The nipple is at the level of 4th intercostal space. Around  15-20 lactiferous  
ducts  pierce the nipple. Areola is a circular pigmented area surrounding the 
nipple. Areola has numerous modified sebaceous glands. The fibrous strands that 
pass from the dermis into the breast,called the suspensory ligaments of  Cooper12 
anchor the  breast to the overlying skin. 
 
                                         Fig 1:  Anatomy of  breast 
(Collins LC, Schnitt SJ: Breast; In: Mills SE, ed. Histology for pathologists, 
ed.3. Philadelphia: Lippincott Williams & Wilkins; 2007:57-74.) 
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           The breast parenchyma is made up of glandular tissue which is arranged 
into lobes13. The lobe is made up of  terminal duct lobular unit[TDLU] and the 
large duct system. (fig.1).It is made up  of lobule and terminal ductule. Each 
lobule is a cluster of acini.The sub segmental and  segmental ducts connect the 
TDLU with the lactiferous(collecting) duct. The lactiferous duct opens in to the 
nipple. The fusiform dilatation that is present between the lactiferous and 
segmental duct  is called the lactiferous sinus 14  
Blood supply  
            The blood supply of breast is by15,16, 
(i) Internal thoracic artery. 
(ii) Axillary artery 
(iii) Lateral branches of posterior intercostal arteries. 
             The venous drainage16 of the breast is by veins that run along the course 
of arteries forming an anastomotic circle in the subcutaneous tissue beneath the 
nipple-areola complex.  
From this the veins run as, 
      1. Superficial veins  that drain into internal thoracic vein .   
      2. Deep veins that  drain into internal thoracic, axillary and posterior 
intercostal veins.16 
Nerve supply:  
        Nerve supply is by anterior and lateral cutaneous branches of 4th  and 6th 
intercostal nerves.16 
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Lymphatic drainage 
1. Axillary lymph nodes: The anterior group of axillary nodes is the main  
lymphatic drainage17 of the breast.The other groups of nodes that receive 
lymphatic drainage either directly or indirectly are posterior, lateral, central 
and apical groups of nodes .       
2. The internal mammary nodes that are located  along internal thoracic vessels. 
3. Supraclavicular node, cephalic node, posterior intercostal, subdiaphragmatic 
and  subperitoneal lymph plexus16 
Lymphatic vessels of breast: 
1. The overlying  skin of  breast  except nipple and areola is drained by 
superficial lymphatics.which drain  to  the  surrounding  lymph  nodes  like 
axillary, internal mammary, supraclavicular  and  cephalic  node. 
2. The  parenchyma ,nipple  and  areola  of  breast are  drained by the deep 
lymphatics. Axillary nodes drain 75% of lymph, internal mammary nodes 
drain 20% and  the remaining 5 % drain into posterior intercostal nodes.15 
Histology 
             The overlying skin of the breast is composed of keratinizing squamous 
epithelium.This epithelium extends into the orifices of the nipple.This then 
changes in to a double-layered cuboidal epithelium. The  ductal-lobular unit has 
luminal epithelial cells and basally located myoepithelial cells18,19. Luminal cells 
can be either columnar or cuboidal based  on their function. These two cell types 
originate from the pleuripotent cell in the terminal duct. The glandular epithelial 
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system rests on a continuous basement membrane. A few scattered endocrine cells 
may also be found in  the normal breast.           
Breast has two kinds of stroma-The intralobular stroma and the inter 
lobular stroma. The intralobular stroma is made up of fibroblast like cells which is  
hormone responsive, while the interlobular stroma is made up of dense fibrous 
connective tissue and adipose tissue(fig.2). 
The nipple is formed by the lactiferous duct as well as  the sebaceous unit. 
The epidermis of nipple and areola is as same as that of normal skin but has more 
melanin content in basal layer. There may also be a few clear cells called Toker 
cells in the basal layer20.       
The luminal cells in the lobules produce milk. Milk ejection during 
lactation is assisted by the contractile myoepithelial cells. They also produce 
structural support to lobules.20 
 
Fig.2. Higher power view - intralobular stroma with interlobular stroma. 
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Cytokeratin, EMA, lactalbumin and GCDFP-1521are positive in the luminal 
epithelial cells .S-10022, Smooth Musle Actin, calponin23, caldesmon(duct 
portion) and p63(nuclear reactivity) are the markers positive in myoepithelial 
cells..24,25 
Physiology of breast   
The hormones estrogen and progesterone have a major role in the 
development of breast26. The lobules are relatively inactive during the 
proliferative phase.After ovulation, the number of acini  per lobule27 increases due 
to the effect of estrogen and increasing progesterone levels. The intralobular 
stroma becomes edematous. During menstruation, there will be regression of the 
lobules with disappearance of the stromal edema due to fall in  estrogen and 
progesterone levels.  
The breast becomes completely mature and functional during pregnancy. 
The number and size of the lobules progressively increase. These lobules are  
separated by relatively scant stroma. After delivery the luminal cells start  
producing  colostrum  which is rich  in protein. When the progesterone level 
begins to  drop,  in the next 10 days there will be milk secretion which is higher in 
fat and calories. On stopping lactation the epithelial cells undergo apoptosis, the 
lobules regress and become atrophic. But however full regression does not occur. 
During the premenopausal phase, there is involution of the lobules. In elderly 
females the lobules may become completely atrophic. 
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FINE NEEDLE ASPIRATION CYTOLOGY OF BREAST MALIGNANCY  
The methods which are followed in the  investigation of breast  lesion that 
appears suspicious on clinical examination, mammography, sonography, or MRI 
are 
 1) Surgical excisional biopsy 
 2) Core needle biopsy 
 3) Biopsy by aspiration or fine-needle aspiration (FNA) 
FNA is a very useful test when there is low level of  suspicion in the 
diagnosis  of malignancy. Another advantage of FNAC is that it can also be used 
for ancillary tests to study hormone receptor status, to quantify them, to 
determine, proliferation antigen (e.g., Ki 67), and to perform  DNA ploidy 
analysis and to study gene expression. 
The review of literature shows that a French physician, Ku¨n, and a 
German-Swiss pathologist, Lebert, in 1847 and 1851,described the use of a 
cannula to obtain  cell samples from palpable tumors and used the microscope to 
identify cancer. In the 1930s 28,29 Martin and Ellis and Stewart  used Fine-needle 
aspiration biopsy of the breast  for the first  time at Memorial Hospital . 
In the 20th century, Hirschfeld was the first person to use a small-caliber 
needle30for the diagnosis of a solid tumor of the skin which got published in 1912 
.Fine  needle aspiration cytology of tumors has been in use for a very long 
time.This is a popular procedure  because it is  cheap31,32 and is a quick 
procedure.The risks regarding the procedure is low and it has high diagnostic 
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accuracy33,34.The art of  performing  and interpreting  FNA requires expertise and 
proper training.  
It has been proposed by MD Anderson Cancer Center Group  that four to 
six well-visualized cell groups consisting of at least six cells in each cluster and 
more than ten cells per flat sheet constitute an adequate specimen.35,36  It is 
recommended that FNAC should be followed with a biopsy  if the FNA findings 
do not correlate with  clinical or radiologic diagnosis of the lesion.37 The term 
“Unsatisfactory” smear is used for several reasons like  faulty technique, 
obscuring  background debris, poor cellularity etc. 
In the present  era, breast FNA faces new roles and challenges An accurate 
diagnosis is expected through FNAC now-a-days .An accurate assessment of the 
molecular features of  tumor  and hormone receptor evaluation is also expected  in 
FNAC at present. 
The role of FNB in breast lump includes: 1. the assessment of simple cysts 
2. the diagnosis of suspected recurrence or metastasis in cases of previously 
diagnosed cancer, 3. To confirm the diagnosis of inoperable, locally advanced 
cancer, 4.  the preoperative diagnosis of tumors which appear malignant 5. To 
know the diagnosis of any  lump which is clinically palpable, either benign or 
malignant to suggest the line of management, 6. to  obtain  tumor cells for 
advanced studies like DNA analysis, and immunohistochemistry, cell kinetics and 
molecular studies,7.to diagnose impalpable image-detected lumps  which are 
either benign or malignant38,8.To rule out  lymph node involvement.9.diagnosis of 
cystic lesions with suspicious imaging features10.to confirm the diagnosis of 
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breast cancer in cases  where tissue  biopsy is not available, not possible or is 
contraindicated38.  
Fine-needle aspiration (FNA) is a safe, relatively cheap39 and minimally 
invasive technique for the diagnosis of breast lesions, The sensitivity of the test 
increases several fold when it is  correlated  with  clinical  history  and  imaging  
studies. It is also the least expensive method of diagnosis since it does not require 
extensive tissue processing. The use of FNA substantially reduces health care 
expenditure by reducing the number of open biopsies, without compromising 
early detection.FNA does not need sedation or hospitalization, and it is a very 
quick procedure. So, It is the most rapid and most versatile method of breast 
biopsy. 
FNAC  helps a lot  by  saving  patients  from unwanted surgeries  and  
investigations  and  also helps  surgeons  to plan  quickly  and  more  rationally 
.The use of  FNA of axillary lymph nodes has helped a lot  to triage patients for 
appropriate treatment. Patients who turn out to be positive for metastatic deposits 
in lymph nodes are subject  to axillary dissection or neoadjuvant chemotherapy, 
whereas those who are  negative undergo sentinel lymph node mapping. It is 
therefore  regarded  as  an  inevitable  component  of  the preoperative  assessment 
of  pathological  processes.                                              
FNAC is also found to be ideal for patients who take  anticoagulants and 
for lesions that lie close to the skin, chest wall, vessels and implant40. For 
superficial, palpable lesions FNAC is a   relatively simple procedure and takes 
very little time  in experienced hands41,42. The possibility  of complications in 
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FNAC is considerably less. The risk of infection and  haematoma formation 
requiring medical intervention are also extremely  rare (0.2%).The risk of 
pneumothorax also seems to be very less (<0.05%)43. There has also been 
reference in the literature that the incidence of tumour transplantation along the 
needle track by FNA procedure is only about 0.0045%, and even much lower in 
superficially located tumours44.  Another advantage of  FNAC is that it is 
comfortable  for aged or frailty patients with comorbidities 45 
Although, a definitive specific diagnosis is  not possible by cytology in a 
number of cases, a differential diagnosis with an estimate of probability can be 
given  which would help to guide the clinician to decide the most efficient further 
investigations. FNAC also decreases the need for frozen section diagnosis.  
However, the utility of breast FNAC depends on the appropriate  
preparation  of cytological conventional smears . Aspirates are best obtained with 
needles of 23–27 gauge.FNB without aspiration is better  for neoplastic breast 
lesions with  increased cell content. 
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Fig.3-Fine needle aspiration cytology 
                              
The disadvantages of FNAC are risks of false positive diagnosis, false 
negative diagnoses  inadequate cellularity, smearing artefacts and abundant back-
ground blood debris. Another important factor that determines the utility of FNAC 
is the expertise of the person performing FNAC and this factor is equally 
important as sample interpretation to reach the correct diagnosis46,47,.Another 
major disadvantage of FNAC is that many breast lesions  are heterogeneous, and 
the small samples obtained with a  needle may not be representative even if the 
procedure is guided by imaging48.  
Multiple passes may  overcome this problem, but the number of passes  
that can be done is restricted inorder to minimize trauma to the patient. The 
cytological preparations cannot give an idea about  the microarchitectural  pattern 
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of the lesion,which is essential in a number of cases to clinch  the right 
diagnosis.Also,the  small  FNB  sample  may  not be sufficient in many cases to  
perform  ancillary  techniques like immune markers. It is essential that the smears 
are immediately fixed without allowing to dry because drying of smears prior to 
fixation may distort the morphological features of cells.  
One of the major current limitations of FNA biopsy is that it  is  difficult  
to differentiate between atypical ductal hyperplasia (ADH) and  ductal carcinoma 
in situ (DCIS) and to differentiate DCIS from invasive carcinoma which has a 
great  influence on  the patient’s treatment protocol.Another major disadvantage 
of  FNA is it’s inability to label a case of low grade carcinoma as malignant 
lesion. 
However,  Fine-needle aspiration biopsy of the breast has high  degree of  
accuracy with an average sensitivity of 87% 49,50, specificity of 98-100%, negative 
predictive value of 87–99%, and efficiency of 89–99%51The  literature shows that 
the results of fine needle aspiration cytology  are comparable with that of core 
biopsy52,53The accuracy rate of FNA biopsy  can be increased if   the 
cytopathologist who  performs the FNA biopsy immediately assess the  specimen 
adequacy. The false-negative rate varies from 1 to 31%, with an average rate of 
10%.  
Grading of breast carcinoma can be done in FNAC using Robinson’s  
grading system(table.1).In this method, six different cytological parameters like 
cell dissociation, cell size, cell uniformity, nucleolus, nuclear membrane and 
nuclear chromatin are used to grade the tumors. A low-grade carcinoma is 
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characterized by tumor cells mostly arranged in clusters ,cells being monomorphic 
with nuclei being 1-2 times the size of RBCs  and nuclei are small and regular 
with regular chromatin distribution and indistinct nucleolus. A high-grade 
carcinoma  shows  polymorphic tumor cells with nuclei of varying size and shape, 
distinct nucleoli, irregular nuclear membrane, and coarse and irregular chromatin. 
A score of 1-3 was given to each of these parameters and the tumor was graded by 
adding up the scores. Tumors that scored in the range of 6-11 were graded I,scores 
of 12-14 were graded II and scores of  15-18 were graded III.  
Table.1.Robinson’s  grading system for carcinoma breast 
 SCORE 1 SCORE 2 SCORE 3 
CELL 
DISSOCIATI
ON 
MOSTLY IN 
CLUSTERS 
SINGLE CELLS AND 
CLUSTERS 
MOSTLY IN 
SINGLE 
CELLS 
NUCLEAR 
SIZE 
1-2 TIMES THE 
SIZE OF RBC 
3-4 TIMES THE SIZE OF 
RBC  
>5 TIMES 
THE SIZE OF 
RBC 
CELL 
UNIFORMIT
Y 
MONOMORPHI
C 
MILDLY PLEOMORPHIC PLEOMORP
HIC 
NUCLEOLI INDISTICT/SM
ALL 
NOTICEABLE ABNORMAL 
 
NUCLEAR 
MARGIN 
SMOOTH SLIGHTLY 
IRREGULAR/FOLDS/GRO
OVES 
BUDS AND 
CLEFTS 
CHROMATI
N PATTERN 
VESICULAR GRANULAR CLUMPING 
AND 
CLEARING 
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LIQUID-BASED CYTOLOGY  
Liquid Based Cytology is a technique in cytopathology,in which the 
samples are prepared for examination by collecting samples in a liquid 
preservative medium before the cells are transferred on to the slide. 
Liquid-based preparations excel  conventional smears because the cells are 
better fixed with decreased background debris, and almost complete transfer of 
cells from the needle hub in to preservative solution occurs. Liquid-based 
cytology can offer a more definite diagnosis, because  the residual material in the 
solution can be embedded in paraffin blocks and it is possible to get  sections with 
appearance similar to those observed in routine histological sections.LBC reduces 
false positive and false negative results and optimises the processing flexibility. 
Increase the cellularity in a defined area and can be used to prepare duplicate and 
triplicate slides.It can also provide material for the purpose of study of  ploidy 
analysis and immunohistochemistry .54Another benefit of LBC is that it is easier 
and faster to screen and interpret LBPs because the cells are in small areas with 
clear background. 
SurePath (TriPath Imaging, Inc, Burlington, NC), ThinPrep 2000 System 
(Cytyc Corp, Marlborough, MA), MonoPrep™ (MonoGen, Inc., 
Lincolnshire,Ill.), which was approved in 2006, are three  systems currently 
approved by the FDA .  
In this method, the sample is collected using 23-27G needle in the 
conventional manner.The material in the hub of the needle  is  then rinsed into the 
fixative . This material is allowed to stand for a minimum of  30 minutes and is 
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then centrifuged for about 10 minutes at 1000 rpm and the supernatant removed. 
Smears are made from the sediment on a cytospin and stained with haematoxylin 
and eosin (H&E) by applying Harris haematoxylin for 4 minutes.The smear is 
then rinsed in water, differentiated in 1%acid-alcohol for 3 seconds, rinsed in 
water, blued in Scott’s solution for 2 minutes and counterstained in 1% eosin for 
30 seconds. Smears are then dehydrated through ascending grades of alcohol, 
cleared in xylene and coverslipped on DPX.    
 
 
Fig.4.liquid based cytology-cytospin 
 
The quality and cellularity of the samples largely depends on the number of 
FNA passes and the skills of the practitioner performing the procedure. Compared 
to conventional FNAC, LBC generally shows presence of small clusters, loss of 
cohesion and three-dimensional configuration  which may lead to an erroneous 
diagnosis of malignancy. The quality of LBC preparations are similar or slightly 
superior in comparison to CS. 
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The cytomorphological features of conventional FNAC and LBC were 
compared and analysed in various studies based on the parameters like cellularity, 
background, monolayers, cell architecture and nuclear details and a scoring was 
given as described in the table given below(table.2 and table.3) 
 
Table.2.Scoring of Cytomorphological features of breast malignancy in 
FNAC and LBC 
Cytologic features 0 1 2 3 
cellularity zero scanty adequate abundant 
Back ground 
debris 
zero occasional Good 
amount 
abundant 
Informative 
background 
absent Present  - - 
monolayer absent occasional Good 
amount 
- 
Cell architecture Non-
recognized
Moderately
recognized 
Well 
recognized 
- 
Nuclear details poor fair good excellent 
Cytoplasmic 
details 
poor fair good excellent 
 
.                                   
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Table.3.Comparison of  conventional FNAC and LBC 
 
FEATURES CONVENTIONAL FNAC LBC 
Cellularity adequate adequate 
Background 
blood-debris 
Good amount occasional 
Informative 
background 
present absent 
Monolayer occasional Good amount 
Cell 
architecture 
Well recognised Well recognised 
Nuclear details excellent good 
Cytoplasmic 
details 
excellent good 
 
Obscuring elements and air-drying and spreading artifacts are significantly 
reduced in  LBC preparations. Although the quality of FNA specimens depends 
largely on the skills of the practitioner obtaining the samples, the problem of poor 
smear preparations may be solved by collecting the material in the appropriate 
vials provided by the different LBC systems. 
 
 
21 
 
CARCINOMA BREAST-FINE NEEDLE ASPIRATION CYTOLOGY 
DUCTAL CARCINOMA-NOS TYPE 
The characteristic features of ductal carcinoma include cellular smears 
composed of  dyscohesive clusters of ductal epithelial cells with cells having 
scanty cytoplasm and nuclei showing pleomorphism and hyperchromasia. 
Background shows no bipolar naked nuclei at all.  
Using the classification schema based on World Health Organization 
criteria54,55 in  FNA specimens breast carcinoma can be divided into  morphologic 
subtypes.Among the favorable breast carcinomas are pure mucinous (colloid), 
true medullary, tubular carcinoma, adenoid cystic carcinoma, papillary carcinoma, 
and secretory carcinoma. Unfavorable breast malignancies include metaplastic 
carcinoma, inflammatory carcinoma, pleomorphic lobular carcinoma, and 
sarcomas 
 Medullary Carcinoma  
Smear studied shows cells arranged in loose syncytial aggregates56 and  as 
singly scattered cells admixed with bizarre tumor cells with pleomorphic high-
grade nuclei,having prominent nucleoli. Background shows numerous  
lymphocytes and plasma cells57 
Mucinous (Colloid) Carcinoma 
In this subtype,smears studied show aggregates and clusters of  uniform 
tumor cells admixed with  occasional  signet ring58 cells  in the background of 
abundant mucin59,60 
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Tubular (Well-Differentiated) Carcinoma  
Moderately cellular smears composed of cells arranged in  angulated, open 
rigid tubules  with  individual cells showing  only mild  atypia and background 
shows no bare nuclei.61,62 
Papillary Carcinoma 
Smear studied shows cells arranged in papillaroid clusters , with individual 
cells showing mild to moderate atypia.63,64There are no bipolar nuclei in the 
background and few hemosiderin laden macrophages are seen. 
 Micropapillary Carcinoma 
In micropapillary carcinoma, smears studied  shows  lesion composed of  
cells arranged in  tightly cohesive clusters with angulated or scalloped borders 
with individual cells having naked pleomorphic  nuclei seen in the  absence of 
papillary fronds with fibrovascular cores.65,66.  
Secretory Carcinoma  
Smear studied shows  cells arranged singly and in small clusters with 
individual cells showing mild atypia .Background shows abundant eosinophilic 
colloid like material . 
Apocrine Carcinoma 
Smears studied shows numerous singly scattered cells and cells arranged in 
syncytial fragments with individual tumor cells having abundant eosinophilic 
granular cytoplasm and large nuclei with prominent nucleoli.68. 
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 Lobular Carcinoma 
Smears studied from lobular carcinoma shows singly scattered cells  and 
cells arranged in small clusters with individual cells being uniform cells with  
scanty cytoplasm, central vesicular nuclei with smooth nuclear membrane and 
inconspicuous nucleoli.69 Nuclei show budding and moulding. Other features  that 
are common in  lobular carcinoma are  intracytoplasmic vacuoles, grooving of 
nuclei and linear arrangement of the cells70. 
Inflammatory Carcinoma 
The characteristic feature of this lesion is that grossly, the tumor apperars  
hyperemic, engorged, and edematous, with peau d’orange  skin appearance. 
Smears studied are  paucicellular with tumor cells  arranged in tight, three-
dimensional clusters and individual cells show pleomorphic, hyperchromatic 
nuclei and increased N/C ratios71.  
Paget’s Disease 
Paget’s disease clinically presents with an eczema-like change of the nipple 
and areola overlying the breast mass. Smear studied shows scattered tumor cells 
with abundant pale cytoplasm, pleomorphic, hyperchromatic nuclei  in a   
background showing abundant necrosis, few squamous cells and numerous 
inflammatory cells. 
Metaplastic Carcinoma 
Smear studied  from  metaplastic carcinoma shows  mixed population of 
malignant ductal cells, spindle cells, and multinucleated giant cells . The 
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undifferentiated spindle cells  forms the sarcomatoid component and shows 
chondrosarcomatous or osteosarcomatous differentiation72,73.  
Squamous Cell Carcinoma of the Breast 
Smear studied from squamous cell carcinoma shows sheets of well-
differentiated or poorly differentiated squamous cells with increased nuclear 
cytoplasmic ratio with  some of the cells showing  intracytoplasmic keratinization 
of the cells and intercellular bridges and few cells show a tendency to spindle. 
CARCINOMA OF BREAST-HISTOPATHOLOGY 
Breast cancer is the most common solid epithelial malignant tumor in 
women.The younger age group shows increase in frequency in carcinoma 
breast.The incidence of breast carcinoma is around  200 fold  more common in 
women as compared to that in men.Breast cancer can be divided into two 
principal categories- in situ carcinoma and  invasive carcinoma. 
DCIS is defined as a proliferation of malignant epithelial cells in 
parenchymal structures of the breast and is distinguished from invasive carcinoma 
by the absence of microscopic stromal invasion across the limiting basement 
membrane.  
DCIS can be classified in to low grade and high grade based on nuclear 
grade.74 High-grade DCIS  refers to those tumors which are negative for hormone 
receptors and positive for HER-2 and p53.They also exihibit a high proliferation 
rate,while  low-grade DCIS is typically negative for HER-2 and p53 and is 
positive for hormone receptors  and has a low proliferation rate75.  
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High Nuclear-Grade Ductal Carcinoma in Situ 
Section studied shows lesion composed of  large pleomorphic cells with 
increased nuclear cytoplasmic ratio. The nuclei in this form of the disease are 
typically more than two and a half to three red blood cells in diameter76.The 
chromatin is typically coarse, and large nucleoli are common.Atypical mitoses  
and necrosis are common. A common feature seen in this type of  lesion is a duct 
filled with solid pattern of  tumor cells  in the central part of which there is 
necrosis, known as comedo DCIS. 
Low Nuclear-Grade Ductal Carcinoma in Situ  
This is composed of evenly spaced cells with small regular nuclei. The 
nuclei are typically less than two red blood cells in diameter and have indistinct 
nucleoli.77.The patterns most commonly seen in this type of lesion are cribriform  
and micropapillary architecture.The neoplastic cells form geometric punched-out 
spaces or bulbous projections around which the cells are polarized. Mitoses and 
necrosis are not common. 
Intermediate Nuclear-Grade Ductal Carcinoma in Situ 
In intermediate nuclear-grade DCIS, the nuclei show less pleomorphism 
than in high-grade disease  but also lacks the uniformity of the low-grade 
type.Other features of this tumor are indistinct nucleolus78,minimal necrosis and 
cell polarization. The tumor may show  solid, cribriform, or micropapillary 
pattern.  
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 Invasive Carcinoma 
Invasive carcinoma of the breast was clinically regarded as a single entity 
in the past, histologic and molecular analysis have demonstrated that breast cancer 
is a heterogeneous disease, composed of morphologically and genetically distinct 
entities with different molecular profiles, behavior, and response to therapy. 
Clinically, invasive breast cancer is classified according to primary tumor size, 
lymph node status, and local extent and presence of distant spread. At the 
morphologic level, breast cancer is classified according to histologic types and 
grades.  
Invasive Carcinoma of No Special Type 
Invasive ductal carcinoma of no special type (ductal NST) refers to a group 
of tumors that do not fall under a specific histologic subtype. Ductal NST is the 
most common type of  invasive carcinoma79. The majority of cancers in male 
breasts are ductal NST.  
The carcinoma cells may be arranged in syncytial sheets or cords   or be 
diffusely infiltrative with individual cells having  abundant, eosinophilic 
cytoplasm and nuclei show pleomorphism and hyperchromasia.Stroma may be 
either cellular or abundant hyalinization may be seen. For a tumor to be typed as 
ductal NST, it must show the nonspecialized pattern in over 50% of its mass, as 
judged by thorough examination of representative sections. If the ductal NST 
pattern comprises between 10% and 49% of the tumor, the rest being of a 
recognized special type, then it will fall into one of the mixed types80. A variant  
known as  pleomorphic carcinoma, is composed of  proliferation of pleomorphic 
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and bizarre tumor giant cells comprising more than 50% of the tumor cells in a 
background of adenocarcinoma or adenocarcinoma with spindle and squamous 
differentiation.  
Infiltrating Lobular Carcinoma 
Infiltrating lobular carcinoma is the second most common  type of breast 
cancer. It is usually associated with older age81 ,larger tumor size, lower histologic 
grade, and positive hormone receptors. Infiltrating lobular carcinoma less 
frequently shows perineural or lymphovascular invasion82.  
The classic subtype accounts for approximately 40% of infiltrating lobular 
carcinomas. The defining histologic features shared by classic examples are 
populations of small to moderately sized cells that lack cohesion and are 
individually dispersed through fibrous tissue or arranged in single files or linear 
cords that invade the stroma, usually with little host reaction or disturbance to the 
background tissue architecture83. The cords and strands are one or two cells thick; 
however, broader bands may be seen, and, when prominent, they constitute the 
trabecular variant of lobular carcinoma. The neoplastic cells are relatively uniform 
and have round or notched ovoid nuclei with inconspicuous nucleoli and scanty  
cytoplasm. The nuclei are often eccentrically placed and exhibit little 
pleomorphism, and mitoses are infrequent. 
The majority of infiltrating lobular carcinomas are positive for ER(80%-
95%), a rate higher than the 70%-80% observed in ductal NST tumors) and 65% 
to 75% are positive for PR. Double hormone receptor–positive tumors constitute 
70% to 75% of tumors, whereas double negatives are less than 5%. Apart from the 
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high-grade pleomorphic variant, HER-2 overexpression and proliferation rates are 
lower than reported in ductal NST. A high proportion of lobular carcinomas 
express carcinoembryonic antigen, and its intensity tends to correlate with mucin 
secretion.  
Tubular Carcinoma 
Tubular carcinoma of the breast is a rare  histologic subtype of  invasive 
breast cancer. Tubular carcinoma  generally shows favorable prognosis.Tumor 
size is smaller;  has low incidence of  lymph node metastases, low incidence of 
recurrences; and a very favourable overall survival.84 
The characteristic feature of tubular carcinoma is the presence of open 
tubules, composed of a single layer of  cuboidal cells enclosing a clear lumen. 
These tubules are generally oval or rounded and often appear angulated and 
haphazardly arranged . The epithelial cells are small to moderately size and 
regular, cuboidal, or columnar in shape and contain rounded or oval 
hyperchromatic low-grade nuclei with little nuclear pleomorphism and 
inconspicuous nucleoli. Apical snouts are frequent but not pathognomonic. 
Mitoses are rare. Calcification may be seen in the stroma85. 
For a tumor to be confirmed as tubular it must exhibit a clearly tubular 
morphology in over 90% of the lesion86. If a tumor contains less than 90% 
tubules, it enters the tubular mixed, ductal, and special type or miscellaneous 
category. More than 90% of tubular carcinomas are positive for ER and 70% to 
80% positive for PR, whereas HER-2 amplification is vanishingly rare. 
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Tubular Mixed Carcinoma 
To be included in the tubular mixed category, a tumor must have a stellate 
configuration with central fibrosis enclosing tubular structures and an infiltrating 
border of variable thickness composed of cords or sheets of cells with the features 
of ductal NST carcinoma . Central elastosis is usually present. A minimum cut off 
point for tubule formation of 50% is now used in routine practice86. 
Invasive Cribriform Carcinoma 
Invasive cribriform carcinoma has been applied to this tumor because it 
exhibits a sieve-like growth pattern similar to that seen in conventional intraductal 
cribriform carcinoma. It is composed of rounded and angulated masses and 
islands of small regular epithelial cells embedded in a variable amount of 
collagenous and reactive-appearing desmoplastic stroma87. The nuclei are dense, 
with little pleomorphism and infrequent mitoses. Within the invasive islands, 
arches of cells  form well-defined punched-outspaces containing variable amounts 
of mucin-positive secretion and sometimes microcalcifications. For a tumor to be 
included in the cribriform category this pattern must form at least 90% of the 
lesion, with the exception that a tumor with 50% or more can be accepted if the 
rest of the lesion is composed of pure tubular carcinoma. 
Mucinous Carcinoma 
Microscopically the tumors consist of small islands or clusters of generally 
uniform, round epithelial cells (10-20 cells) set within extensive lakes of 
extracellular mucin with mucicarmine-,MUC-2–, and MUC-6–positive content88. 
These mucous lakes are divided by delicate fibrous septa into compartments. The 
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islands  form a trabecular, cribriform, or papillary pattern, sometimes with a 
tubular arrangement with individual cells being  small to medium  in size, with 
minimal amounts of eosinophilic cytoplasm and darkly staining nuclei that exhibit 
comparatively little  nuclear pleomorphism.Pure tumors should comprise entirely 
of mucinous carcinoma. 
Pure mucinous carcinomas consistently express ER (100%) and PR (70%), 
lack HER-2 expression (97.1%), and show a relatively low level of genetic 
instability. 
Medullary Carcinoma 
The epithelial cells are arranged in interconnecting sheets, forming a 
syncytial network. They are large and pleomorphic with abundant cytoplasm and 
vesicular nuclei containing one or several nucleoli and showing a proportion of 
bizarre nuclei and a high mitotic count, that is, histologic grade 3. This pattern 
should comprise at least 75% of the tumor area with  no glandular or tubular 
component at all.The intervening stroma is scant and contains a moderate  to 
severe lymphoplasmacytic infiltrates and the border of the tumor is pushing rather 
than infiltrative.Medullary carcinomas typically lack ER and PR expression, as 
well as HER-2 amplification (triple negative), and show high proliferative and 
apoptotic activity. 
Atypical medullary carcinoma 
Tumors bearing some but not all the features of medullary carcinoma have 
been designated as atypical medullary carcinoma 89. A lesser degree of lymphoid 
infiltrate, microscopic infiltration beyond the main border, or areas of dense 
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fibrosis may be seen. A tumor may also be classified as atypical medullary if up to 
25% is composed of ductal NST and the rest is classic medullary carcinoma. 
Invasive Papillary Carcinoma 
The characteristic feature is the presence of papillary structures with 
associated fibrovascular cores. Frank invasion is recognized by the presence of 
neoplastic cells with infiltrative appearances beyond the zone of reactive stroma 
and extending into mammary parenchyma and fat. Cytologic appearances are 
varied, and nuclear pleomorphism and increased numbers of mitoses may be 
seen90.  
Invasive micropapillary carcinoma   
This is applied to an uncommon and unusual variant of invasive breast 
carcinoma in which epithelial tufts forming micropapillae without a fibrovascular 
core are located within clear stromal spaces resembling dilated vascular 
channels91. Neoplastic cells show a moderate to marked degree of nuclear 
pleomorphism and low mitotic activity, and they lack necrosis and a lymphocytic 
reaction. The neoplastic cells maintain their architectural features in the metastatic 
sites.92 
Mixed Types 
In mixed ductal and lobular carcinoma are distinct ductal NST and 
infiltrating lobular elements, the former amounting to between 10% and 90% of 
the tumor. The mixed ductal and special type of carcinomas includes any tumors 
composed of a mixture of a special tumor type, such as tubular, invasive 
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cribriform, or mucinous carcinoma with ductal NST carcinoma in which the latter 
forms over 10% of the tumor mass.  
PROGNOSTIC  FACTORS IN CARCINOMA BREAST 
They can be divided broadly into two groups, traditional and molecular. 
The traditional factors can be assessed during conventional examination and 
histologic evaluation of tumors.  Techniques for assessment of molecular markers 
are less widely available. The outcome for women with breast cancer varies from 
a normal life expectancy to having only10% chance of being alive in 5 years .This  
information is important to create awareness in patients about the disease.     
Traditional Pathologic Factors  
The following pathologic factors, all of which are relatively simple to 
assess, have been shown to provide clinically useful prognostic information, to a 
greater or lesser degree.93,94 
 (1)Tumor Size 
 (2) Lymph Node Status  
 (3) Histologic Type  
 (4) Histologic Grade 
 (5) Lymphovascular Invasion 
 (6) Necrosis 
 (7) Stromal Features 
 (8) patient age  
 (9)family history 
 (10)Inflammatory cell infiltrate 
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 (11)apoptosis 
 (12)angiogenesis 
 (13)fibrotic foci 
 (14)perineural invasion 
1.Tumor Size 
The measured gross size represented by the largest diameter of a mammary 
carcinoma is one of the most significant prognostic variables. Studies have shown 
that survival decreases with increasing tumor size and that there is a coincidental 
rise in the frequency of axillary nodal metastases.95 
2.Lymph Node status 
In the absence of distant metastases ,one of  the most important prognostic 
factors for invasive carcinoma is axillary lymph node status.With no nodal 
involvement, the 10-year disease-free survival rate is close to 70% to 80%; The 
10-year disease free survival decreases significantly with increase in the number 
of nodes involved. 
3.Histologic sub- type 
Various special types of invasive carcinomas (tubular, mucinous, 
medullary, lobular, and papillary) have better disease free survival than NST 
cancers. 
4.Histolgical grading of ductal carcinoma 
           Grading of breast cancer was first attempted by Green though in 1925.He 
used about 18 features and it is not popular. In 1993 Haagensen evaluated around 
15 histological features to grade carcinoma breast. 
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           The most popular grading system till date was proposed by Bloom in 
1950.92His grading system was based on  three main features which includes 
degree of tubule formation ,nuclear features and mitotic activity .He classified 
breast carcinoma into 2 categories –low grade and high grade tumors.  
             In 1957 this classification was upgraded by modifications of Bloom and 
Richardson96It is also based on degree of tubule formation, nuclear pleomorphism 
and mitotic activity. But  in this classification score of 1 to 3 was given to each 
criteria according to mild ,moderate or marked degrees. A total score of  3 to 9 
was given as follows,                                                                                                                       
 
Table 4 :  Bloom And Richardson grading system 1957 
 
 Elston- Ellis modification of the Scarff-Bloom-Richardson grading system  
 (Nottingham grading system [NGS])96 
 
Tubule Formation 
Majority of tumor (>75%) -1 point 
Moderate degree (10%-75%)- 2 points 
Little or none (<10%) -3 points 
Score          3-5      Grade 1 Well differentiated tumors 
Score         6-7    Grade 2 Moderately differentiated tumors 
Score         8-9    Grade 3 Poorly differentiated tumors 
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Nuclear Pleomorphism 
Small, regular uniform cells- 1 point 
Moderate increase in size and variability -2 points 
Marked variation -3 points 
Mitotic Counts 
           Mitotic count is also graded as 1-3.But it depends on the field diameter 
used. Mitotic figures are to be counted from the most mitotically active area.10 
high power fields should be counted from the same area but need not to be 
contiguous. Poorly preserved area should be ignored.  
Table 5:Scoring of mitotic count 
Field diameter0.59mm Field diameter 0.44mm score 
0-9 0-5 1 
10-19 6-10 2 
>20 >11 3 
 
Table.6.Final grading of carcinoma breast 
GRADE SUM OF POINTS 
I 3–5 
II 6–7 
III 8–9 
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5.  Lymphovascular Invasion 
Lymph node metastases is often accompanied by involvement of vascular 
spaces by tumor cells.So, in node negative cases , vascular invasion confers a  
poor prognosis for survival  and a risk factor for local recurrence. Infiltration of 
tumor cells into the lymphovascular spaces in dermis is also  associated with poor 
prognosis. 
6. Necrosis 
Tumor necrosis is defined as the “presence of confluent necrosis of any 
dimension in a section of invasive cancer that could be distinguished at 
intermediate magnification. It a significant predictor of time to recurrence and 
overall survival with 10-year follow-up97 
7. Stromal features 
Tumors that contain minimal stromal reaction tend to have the 
circumscription, poorly differentiated nuclear and histologic grade, and a 
prominent lymphoplasmacytic reaction. They also tend to be estrogen-receptor 
negative. On the other hand, densely fibrotic or scirrhous carcinomas are more 
likely to be stellate, moderately differentiated, and to have little 
lymphoplasmacytic reaction. A greater proportion of these lesions are estrogen-
receptor positive. 
8. Patient age 
It is found that if age at the onset of disease is less than 50 years of age the 
patient has the best prognosis and the survival rate declines after the age of 50 
years. 
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9. Family history 
The presence of history of breast cancer in family  is associated with poor 
prognosis. 
10. Inflammatory cell infiltrates 
Various studies have shown that prominent inflammation is  associated 
with high histologic grade and better survival.When Grade 3 ductal NST 
carcinoma was associated  with prominent inflammation  it showed a better 
prognosis than those without prominent inflammation.98 A subsequent study 
showed that tumor infiltrating CD8-positive T cells were associated with 
improved survival.99 
11. Apoptosis 
Apoptosis is  a mode of cell death.It is characterized by cell shrinkage and 
rounding,chromatin condensation, fragmentation of the nuclei (pyknosis and 
karyorrhexis) with intracellular and extracellular chromatin fragments and 
cytoplasmic fragmentation with cytoplasmic blebs.High apoptotic index is shown 
to be associated with high grade, with a high proliferative activity, and with 
absence of hormone receptors. 
12. Angiogenesis 
Angiogenesis refers to proliferation of new capillaries from the existing 
vascular network. Angiogenesis  is required  for  growth of the tumor and for  
metastases. Increased microvessel density in breast cancer has consistent  
association with lymph node metastasis and reduced survival in lymph node– 
negative breast cancer.100,101 
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13. Fibrotic foci 
Fibrotic focus is a region seen in invasive carcinoma of breast that replaces 
the central necrotic area ,which is mostly made up of fibroblasts and collagen 
fibers.. This is found to be  associated with basal subtype, an expansive growth 
pattern, hypoxia and angiogenesis, activated wound-healing signature and a poor 
prognosis.102 
14. Perineural invasion 
Perineural invasion is often seen in high-grade tumors which show vascular 
invasion and involvement of  lymph nodes.103 
MOLECULAR PROGNOSTIC AND PREDICTIVE  FACTORS  
A prognostic factor is defined as a characteristic of a patient or tumor at the 
time of diagnosis that can be used to provide information on clinical outcome 
(relapse and death) in the absence of therapy, whereas a predictive factor is 
defined as a characteristic that provides information on likelihood of response to 
therapy. In breast cancer, assessment of hormone receptors and HER-2 gives an 
idea about  response of the malignancy to chemotherapy and endocrine therapy. 
The development of methods to detect antigens on tissue sections with antibodies 
was a major advance in surgical pathology104,105. Routine assessment of ER, PR, 
and HER-2 status on all primary invasive and recurrent breast cancers is  
recommended by the American Society of Clinical Oncology/College of 
American Pathologists. 
Immunohistochemical (IHC) studies are most frequently used  for 
classification of tumors,to identify insitu lesions/invasive lesions and to determine 
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prognostic and predictive factors.Estrogen and progesterone receptors are 
localized to the nuclei of epithelial cells.In normal resting breast the nuclei  of 
approximately 7% of epithelial cells are immunoreactive for estrogen receptor 
while a higher proportion of cells show positivity in lobular than in ductal 
cells.106,107  
Immunohistochemistry refers to process of employing antibodies as 
specific probes for the visualization of cell and tissue bound antigens.  
Immunoenzymatic techniques employing antibodies conjugated with enzymes are 
used to identify antigen-antibody reaction108,109.Immunochemical approach for the 
demonstration of ER and PR is highly sensitive and specific. 
ESTROGEN RECEPTOR 
Estrogen receptor is a steroid receptor situated in the nucleus of the cell. 
Hormone diffuses in to the nucleus to bind to the receptor. The important function 
of the genes  regulated by steroid receptors is monitoring cell growth and this 
effect of ER determines the behavior and treatment of breast cancer. 
This receptor and can be identified by different  methods like ligand 
binding, immunoassays, and immunocytochemistry. The inhibition of these 
receptors by various methods like oophorectomy, estrogen agonists (selective ER 
modulators) or indirectly by  preventing the conversion of androgens to estrogen 
(e.g., aromatase inhibitors), forms  a major target of breast cancer endocrine 
therapy.110,111 
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PROGESTERONE RECEPTOR    
PR is an estrogen-regulated gene and it’s positivity indicates a functioning  
ER pathway.Various data have shown that determination of  PR assessment in 
carcinoma breast have definite prognostic and predictive significance112.                   
PR-positive cancers are likely to have a better prognosis than PR-negative tumors 
and they can also predict response to endocrine therapy .113 
Her-2/neu 
Her2/neu is a proto-oncogene which encodes a transmembrane protein that 
shares homology with epidermal growth factor . Overexpression of Her2/neu in 
breast cancer implies that the tumor has worse  prognosis than tumors which are 
Her2/neu negative114. The presence of Her2/neu is also used to predict whether 
patients respond to a monoclonal antibody to Her2/neu (Herceptin).115  
IMMUNOHISTOCHEMISTRY 
Immunohistochemistry (IHC) or immunocytochemistry is the application 
of immunologic principles and techniques to demonstrate specific antigens in cells 
and tissue based on the antigen antibody interaction and it exploit the specificity 
at light microscopic level. 
              Various stages of development of Immunohistochemistry include 
peroxidase–antiperoxidase method (1970), alkaline phosphatase labeling 
method(1971), avidin biotin method (1977) and two layer dextrin polymer 
technique(1993). 
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Steps of immunohistochemistry: 
Antigen retrieval :Antigen retrieval is done to unmask the antigen determinants 
of fixed tissue sections.This can be done by 
1. Proteolytic enzyme digestion 
2. Microwave antigen retrieval 
3. Microwave and trypsin antigen retrieval 
4. Pressure cooker antigen retrieval 
Proteolytic enzyme digestion:  
          Enzymes like trypsin and proteinases are used to breakdown  the formalin 
cross linkages and unmask the antigen determinants. But  there is a disadvantage 
of antigen destruction and inadequate digestion. 
Microwave antigen retrieval: 
        In this formalin fixed paraffin sections are boiled in various buffers for rapid 
and uniform heating. Currently this is the most common method used. 
Pressure cooker antigen retrieval: 
        In this method also the tissue sections are boiled in buffers to unmask the 
antigens. This method is used to retrieve large number of slides. 
Detection systems: After adding specific antibodies to the antigens, the antigen 
antibody complex should be detected. This is done by direct and indirect methods. 
Direct method: 
      The primary antibody is directly conjugated with flurochrome. Commonly 
used flurochromes are horse radish peroxidase and alkaline phosphatase.  
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Indirect method : 
        It is a two-step method .First the labeled secondary antibody reacts with 
primary antibody which is bound to specific antigen. The use of peroxidase 
enzyme complex or avidin biotin complex further increases the sensitivity of 
immunohistochemical stains. 
IMMUNOCYTOCHEMISTRY 
Immunocytochemical methods for ER and PR are readily adaptable to 
cytological materials including fine needle aspirates, touch imprints, malignant 
effusions, cytospins, and ThinPreps.116 The ability to perform ER and PR in 
cytological preparations is particularly valuable for patient management issues, 
including patients who require preoperative chemotherapy and in cases of 
recurrent or metastatic breast cancer.  
Interpretation of ER,PR and Her-2/neu  
Many different methods are currently used to report the results of IHC 
studies for ER and PR. One method that is commonly used is the Allred score 
method117. Patients with carcinomas that scored 3 (<1% of cells with intermediate 
intensity or 1% to 10% of cells with weak intensity) or above had improved 
disease-free survival when treated with endocrine therapy.  
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Table.7.  ER AND PR –ALLRED SCORE 
             
Proportion score 
(PS) 
% positive cells Intensity score 
(IS) 
Intensity of 
positivity 
0 0 0 None 
1 <1% 1 Weak 
2 1%-10% 2 Intermediate 
3 10%-33% 3 Strong 
4 33%-66%   
5 >66%   
 
Total score(PS+IS) Interpretation 
0,2 NEGATIVE 
3,4,5,6,7,8 POSITIVE 
 
(Hammond ME, et al, American Society of Clinical Oncology/College of 
American Pathologists Guideline Recommendations for Immunohistochemical 
Testing of Estrogen and Progesterone Receptors in Breast Cancer, J Clin Oncol 
2010 Apr 19). 
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Table.8.HER2/neu score 
SCORE CRITERIA 
0 (Negative) No staining  or if present,only in 
<10% of cells 
1+ (Negative) Faint or  weak staining in >10% of 
tumor cells and only a portion of the 
membrane is positive. 
2+ (Equivocal) Weak to moderate staining  in >10% 
of tumor cells and there is complete 
immunoreactivity. 
3+(Positive) circumferential intense 
and uniform membrane staining is 
shown by more than 30% of the 
tumor cells . 
A homogeneous (chicken wire) 
pattern should be present. 
 
Recommended guidelines by ASCO 
1. The type of fixative that can be used is 10% neutral buffered formalin 
2. The ideal time of fixation should be between 6-48 hrs 
3. The most reliable antibody is rabbit monoclonal antibody,4B5                            
                 If the results are 2+ it is recommended to perform FISH. Recently 
ASCO/CAP118 has published their recommendations for HER2/neu testing. 
The result is taken as positive in case of ,  
                   1.3+ staining by IHC 
                   2. More than 6 HER2/neu gene copies in FISH                  
                   3. FISH ratio >2.2 
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The result is taken as negative when there is 
           1.  0 or 1+ positivity by IHC 
            2.  < 4 HER2/neu copies per nucleus by FISH 
           3.   FISH ratio <1.8 
PATHOLOGICAL AND CLINICAL IMPLICATIONS OF MOLECULAR 
SUBTYPING OF CARCINOMA BREAST                   
Breast cancer is known to be a heterogeneous disease .So tumors  with the 
same clinicalpathological characteristics tend to exihibit  diversity in disease 
behavior, response to therapy and prognosis. Gene expression profiling studies is 
supposed to be the gold standard method to subtype tumors based on molecular 
features.. As gene expression profiling from formalin-fixed, paraffin-embedded 
samples is not readily available at present ,IHC surrogate panels of estrogen 
receptor (ER), progesterone receptor (PR), HER2 and ki-67 can  be readily used 
to subtype the malignant tumors of  breast. (Nielsen et al., 2004; Livasy et al., 
2006; Carey et al 2007; Hugh et al., 2007;  Cheang et al., 2008). 
The classification of breast cancer at the molecular level  is  according to 
hormone receptor expression and c-erbB-2 (HER-2) status. Other factors like 
lymphovascular invasion and expression of proliferation-associated markers (e.g., 
Ki67), p53, and E-cadherin may also  have biologic and prognostic value.  
With  the use of modern technologies like microarray  analysis, breast 
tumors can be divided in to five molecular subtypes- luminal A, luminal B, 
normal breast–like, HER-2, and basal119.  
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A  dysfunctional BRCA-1 protein is  exihibited by a large number of basal 
tumors. These tumors express p53 or TP53 gene mutation in majority of cases and 
also exihibit  high proliferation indices identified by high number of mitoses or 
increased  Ki67 labeling index. 
Table.9.Molecular subtyping of carcinoma breast 
 Luminal A Luminal B HER2/neu Basal-like 
Gene 
expression 
pattern 
Expression of 
luminal 
cytokeratins, 
and high 
expression of 
hormone 
receptors and 
associated 
genes 
Expression of 
luminalcytokeratins, 
and moderate to 
weak expression of 
hormone receptors.  
High 
expression of 
HER2 and 
other genes in 
amplicon on 
17q12 
Low 
expression of 
ER and 
associated 
genes 
High 
expression of 
basal epithelial 
genes, basal 
cytokeratins 
Low expression 
of ER and 
associated 
genes 
Low expression 
of HER2/neu 
Clinical 
and 
biologic 
features 
ER/PR positive 
& 
HER2/neu 
negative 
ER/PR positive 
HER2/neu- variable 
Higher proliferation 
than luminal A 
 tends to be higher 
histologic grade 
than luminal A 
ER/PR 
negative 
HER2/neu 
positive 
High 
proliferation 
TP53 
mutation 
common 
More likely to 
be high grade 
and node 
positive 
Most ER/PR 
and HER2/neu 
negative (‘triple 
negative’) 
High 
proliferation 
TP53 mutation 
common; 
BRCA1 
dysfunction 
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Histologic 
correlation 
Tubular 
carcinoma 
Cribriform 
carcinoma 
Low grade 
invasive ductal 
carcinoma NOS 
Classic lobular  
Invasive ductal 
carcinoma NOS 
Micropapillary  
High grade 
invasive 
ductal 
carcinoma 
NOS 
High grade 
invasive ductal 
carcinoma NOS
Metaplastic 
carcinoma 
Medullary 
carcinoma 
Treatment 
response 
and 
outcome 
Respond to 
endocrine 
therapy 
Respond to 
endocrine therapy 
not  as good as 
luminal A 
Respond to 
trastuzumab 
(Herceptin) 
No response to 
endocrine 
therapy or 
trastuzumab 
(Herceptin) 
 Response to 
chemotherapy 
variable 
Response to 
chemotherapy 
variable (greater 
than luminal A) 
Respond to 
anthracycline-
based 
chemotherapy 
Appear to be 
sensitive to 
platinum-based 
chemotherapy 
and PARP 
inhibitors 
  Good prognosis Prognosis not as 
good as for luminal 
A 
Generally 
poor 
prognosis 
Generally poor 
prognosis (but 
not uniformly 
poor) 
(Modified from Schnitt SJ. Will molecular classification replace traditional breast 
pathology? Int J Surg Pathol 2010, 18: 162S–166S; and Correa Geyer F, Reis-
Filho JS. Microarray-based gene expression profiling as a clinical tool for breast 
cancer management: are we there yet? Int J Surg Pathol 2009, 17: 285–302) 
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PROGNOSTIC AND PREDICTIVE VALUE OF HORMONE 
RECEPTORS/Her-2/neu  
High-dose systemic therapy which is given  preoperatively in  patients with 
locally advanced or inflammatory carcinoma  is called neoadjuvant therapy.This 
can be either chemotherapy or endocrine therapy. Neoadjuvant chemotherapy  
takes an important place in treatment of operable breast cancer in the hope of 
improving conservative surgery rate of female patients. The major targets of NCT 
is to downstage the tumor load  and to raise the number of surgeries which can 
conserve breast. 
The role of ER,PR and Her-2/neu status in breast carcinoma has been 
extensively studied. Earlier it was believed that ER positive tumors had a better 
prognosis but now it has been established that although ER positive tumors are 
slow growing they do not have a lower metastastatic potential .The significance of 
ER positive tumors is that it predicts the response to tamoxifen. It is also noted 
that women who have an ER Allred score of 6, and above seem to respond better 
when given neoadjuvant hormone therapy.Also, aromatase inhibitors produce 
responses in tumors with lower levels of ER whereas tamoxifen does not. Many 
major clinical trials  have shown that addition of Tamoxifen, a SERM, to 
conventional chemotherapeutic and surgical treatment protocols consistently 
improves disease free survival in women with hormone receptor-positive 
tumors.120 
Her-2/neu  over expression seems to be a weak to moderate independent 
predictor of survival.It  acts as a reliable negative predictor for response to 
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alkylating agents and a moderately positive predictor of response to 
anthracyclines. In a hallmark study carried out by Slamon et al in 1987, HER2 
amplification was verified as a significant independent negative predictor of 
overall survival and time to relapse 121. Since then, HER2 status, as determined by 
either fluorescence in-situ hybridization (FISH) or IHC, has become important for 
prognostic implication and to assess potential response of patients to treatment 
with the monoclonal antibody trastuzumab (Herceptin). Several large, randomized 
clinical trials sponsored by the National Cancer Institute in 2005  have 
demonstrated that  if chemotherapy and Herceptin are used together in patients 
with Her-2/neu positive breast cancer,it can drastically reduce the chance of 
recurrence as compared to those treated with chemotherapy alone.122.                                            
PROGNOSTIC IMPLICATIONS OF HR +/HER2-NEGATIVE BREAST 
CANCER     
Under  HR+/HER2-negative breast cancers, 90-95% of  tumors belong to 
Luminal A and B subtypes. It is shown that in the early breast cancer, Luminal B 
disease has worse prognosis  at 5- and 10-yrs  inspite  of adjuvant systemic 
therapy compared to Luminal A disease123. Apart from  predicting baseline 
prognosis, the Luminal A vs B classification, along with tumour size and nodal 
status also estimates the  residual risk of  late recurrence at a distant site,ie at  5-
10-years of follow-up.124Studies have also shown that  the Luminal B tumours are 
more  chemosensitive than Luminal A tumours125 and Luminal A tumours  which  
have a lower baseline proliferation status than Luminal B tumours seem to  
respond to endocrine therapy better.126 
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 PROGNOSTIC IMPLICATIONS OF  Her-2/neu  POSITIVE CANCERS 
The prognostic implications of  HER-2 gene amplification are (1)it  
predicts  poor  prognosis and response of tumors  to systemic chemotherapy 
(2)HER-2 expression often increases with the absence of hormone receptors and 
vice versa. (3) 
HER-2 positivity often  seems to be  associated with  a relative resistance 
to endocrine therapies.(4)Over-expression of HER-2/neu  implies that the tumor 
responds to trastuzumab (Herceptin)(5)It  is also an important negative predictor 
of overall survival and time to relapse in patients with lymph-node-positive breast 
cancer (Suo et al., 2002). (6)It has also been shown that tumors with increased 
Her-2/neu expression is associated with a poor histologic grade and increased 
lymph node involvement. However, the prognostic implication of  HER-2 
positivity is more in node-positive  cases as compared to node-negative cases.. 
Trastuzumab is a humanized monoclonal antibody against HER-2neu.It is 
known to have immense benefit in patients with HER-2–positive breast 
cancer.Thus with the advent of this drug, it is highly essential to determine  the 
HER-2 status of breast cancer  in pre-operative period to plan treatment. 
Trastuzumab is useful in searly-stage patients with Her2-positive breast cancer. 
The advantages of  trastuzumab is that it reduces the risk of disease recurrence 
and improves overall survival. 
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PROGNOSTIC IMPLICATIONS OF  TRIPLE NEGATIVE CANCERS 
The features of  Basal tumors (triple-negative lesions)  are (1)poor disease-
free survival and overall survival(2) distinct  patterns of recurrence and distant 
metastasis(3) commonly seen in younger patients(4) they are generally  high  
grade tumors with very  high mitotic indices,abundant necrosis, tissue infarction, 
collagen, and hyaline material (5)have pushing borders(6) significant lymphocytic 
infiltrate; and typical or atypical medullary features.(7)their response to endocrine 
therapy or trastuzumab (Herceptin) is very poor.(8)They respond to PARP 
inhibitors(9)They usually show poor prognosis. 
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MATERIALS AND METHODS 
 
The present study is a prospective study to assess and compare  the role of 
Conventional  FNAC  and Liquid based cytology in the pre-operative diagnosis 
and prognosis of carcinoma of breast. . Approval of the Institute Ethical 
Committee was obtained to conduct this research study.  
STUDY LOCATION                             
The study was conducted at  the Department of Pathology, Tirunelveli 
medical college,Tirunelveli. 
STUDY PERIOD 
    The study was conducted over a period from November 2014 to Septemder 
2015 . 
INCLUSION CRITERIA 
FNAC smears diagnosed as carcinoma of breast. 
EXCLUSION CRITERIA 
1. FNAC smears diagnosed as Inflammatory lesions. 
2. FNAC smears diagnosed as benign neoplasms. 
3. FNAC smears diagnosed as atypical ductal hyperplasia. 
4. FNAC smears of breast carcinoma patients on chemotherapy. 
SAMPLE SIZE 
A total of 30 cases of carcinoma breast diagnosed on FNAC were studied. 
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METHODOLOGY 
The details of the patient on the request are verified. This is followed by 
the examination of the patient with special emphasis on features like location of 
the lesion, the presence or absence of skin or chest wall involvement, involvement 
of nipple, tumor size, consistency of tumor and circumscription of the tumor. The 
data are recorded in a format(Annexure 1) 
PREPARATION OF SMEARS 
CONVENTIONAL FNAC 
A  22 to 27-gauge, 1 or 1.5-inch needle attached to a disposable 20-ml 
syringe is used to obtain breast aspirates. The material obtained through first pass 
is used to make four smears. One of them is stained with hematoxylin and eosin 
stain. 
  The remaining smears are used for immunocytochemical staining. 
HAEMATOXYLIN & EOSIN STAINING TECHNIQUE 
PREPARATION OF HAEMATOXYLIN SOLUTION:  
Haematoxylin                           2. 5gm 
Mercuric oxide                         1.25gm 
Potassium alum                       50gm 
Absolute ethyl alcohol              l 25ml 
Sodium iodate                          0.5gm 
Distilled water                          500ml 
PROCEDURE: 
Potassium alum, 50gm is dissolved in 500ml of distilled water by heating 
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and shaking at 600 C. Add solution of 2.5gm of Haematoxylin in 25ml of absolute 
ethyl alcohol and bring rapidly to boil. When it begins to boil, remove from flame 
and add 1.25gm of mercuric oxide or sodium iodate. When the solution is cold 
add acetic acid. 
PREPARATION OF EOSIN SOLUTION: 
Eosin Y                     1gm 
95% Ethanol              80ml 
Glacial Acetic acid     0.2ml 
Distilled water           20ml 
PROCEDURE: 
Dissolve 1gm Eosin Y in 20ml of distilled water and add 80ml of 95% 
etanol and 0.2ml of glacial acetic acid. 
STAINING PROCEDURE: 
1.Xylene 3 changes-2mins each. 
2.90%, 80%, 70% alcohol-10 dips each. 
3. Bring sections to water. 
4. Harris Haematoxylin-15 minutes. 
5. Rinse in tap water. 
6. Differentiate in 1% acid alcohol. 
7. Rinse in tap water. 
8. Lithium carbonate 0.5%- until blue. 
9. Tap water wash. 
10. Eosin-15secs to 2mins depending on age of Eosin. 
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11. Rinse in tap water. 
12. Dehydrate in 95% alcohol. 
13. Absolute alcohol-3 changes-10 dips each. 
14. Xylene 2 changes-10 dips. 
15. Mount in DPX mountant. 
RESULTS: 
Nuclei- Blue  
Cytoplasm, RBCs, Keratin- Pink,  
Eosinophil granules- Orange red 
LIQUID BASED CYTOLOGY 
The material obtained through second pass is rinsed in to U-prep 
cytopreservative solution. It is kept for a minimum of 30 minutes for fixation and 
then centrifuged. The supernatant is discarded and four smears are made from the 
sediment by centrifuging samples using  NANOCYT .Let the slides dry before 
staining. One of them is stained with hematoxylin and eosin as described 
above.and the remaining three slides are used to do immunocytochemical 
analysis(ER,PR and  Her-2/neu). 
The slides are studied under light microscopy and the data are recorded. 
The conventional FNAC smears stained with Hematoxylin and Eosin are graded 
according to Robinson’s criteria.The cytomorphology of conventional FNAC 
smears and LBC are compared and analysed 
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IMMUNOCYTOCHEMICAL EVALUATION: 
               The  three conventional smears and LBC smears for evaluation of  ER 
PR and Her-2/neu  are fixed in absolute alcohol for around 30 minutes. Rabbit 
Monoclonal antibody (Path insitu) is used to bind with primary antigen and is 
detected by adding secondary antibody conjugated with horse radish peroxidase – 
polymer and diaminobenzidine substrate. 
PROCESSING FOR IMMUNOCYTOCHEMISTRY 
 The smears for ICC in conventional FNAC are made on ordinary glass 
slide while those in LBC are made on Poly Lysine coated adhesive slides. 
 The  three conventional smears and LBC smears for evaluation of  ER PR 
and Her-2/neu  are fixed in absolute alcohol for a minimum of  30 minutes. 
 The slides are then kept in TRIS wash buffer for around 2 minutes. 
 Endogenous peroxidase activity is removed by incubating the tissue 
sections with enough drops of 3% peroxide block in a humidity chamber 
for 5minutes.The sections are then washed in TRIS wash buffer. 
 The smears are incubated with primary antibody for around 30 minutes. 
  The tissue sections are then washed in 2 changes of  TRIS wash buffer. 
 The smears are treated with target binder for 15 minutes. 
 The tissue sections are then washed in 2 changes of  TRIS wash buffer 
  The smears are treated with  HRP-polymer DAB for 15 minutes. 
  The tissue sections are then washed in 2 changes of TRIS wash buffer 
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 DAB chromogen (1ml DAB buffer +1 drop DAB chromogen) is then  
added over the smears  and incubated for 4 minutes and then washed with 2 
changes of distilled water. 
 Counterstaining was done with haematoxylin for 30 seconds and  washed 
in running tap water. 
 Dehydration is done by 2 changes of 100 % alcohol. 
 Mounting is done by DPX mountant and observed under microscope 
BUFFER PREPARATION 
Tris wash buffer 
      Tris - 0.605 gm 
           Sodium chloride - 8 gm 
           1 N Hcl - 4ml 
           Distilled water - 1000 ml   
PRECAUTIONS 
1. The glassware used should be dry and clean. 
2. The buffer used should be prepared fresh and the p H should be adjusted 
according to the preferred p H. 
3. The staining procedures are never allowed to dry so they are            
performed under a humidity chamber. 
4. DAB chromogen should be handled and disposed carefully as it is a 
carcinogen. 
5. Primary antibody, DAB chromogen, peroxidase block etc should be stored 
at 4-6ºC. 
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6. Then the slides are counterstained with Mayers Hematoxylin. 
Scoring of ER and PR are done using Allred score (Table.7) and Her-2/neu 
scoring is done as per ASCO guidelines. Membrane staining with 3 + and 2+ 
immunoreactivity were  considered HER2/neu positive. (Table.8) 
Statistical Analysis  
The SPSS software version 11 (SPSS, Chicago, IL, USA) was used to 
perform the statistical analysis of the data.. Mcnemar test ,which is a statistical 
test used on paired nominal data has been used to evaluate the statistical 
difference between the two methods. p value of <0.05 is considered significant. 
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OBSERVATION AND RESULTS 
 
The study analysed the conventional  fine needle aspiration cytology 
samples of 30 cases of malignant lesions of breast along with the corresponding  
liquid based cytology samples to compare the cytomorphology. The study also 
included the assessment of hormone receptor and Her-2/neu status on 
conventional FNAC smears  and liquid based cytology and assess the diagnostic 
and prognostic value of conventional and liquid based cytology.  
 
Table.10.Distribution of Grading of breast cancer in conventional smears 
 
Carcinoma breast Total No. of 
cases(n=30) 
Grade-1 10 
Grade-2 13 
Grade -3 7 
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The percentage of cases with poor cellularity in conventional FNAC is 
23.3%,while that in LBC is 13.3%.When the two methods were combined the 
number of cases with poor cellularity dropped down to 3.3%. 
 
2. BACKGROUND BLOOD-DEBRIS    
Table.14.Amount of background blood-debris in smears 
BACKGROUND 
BLOOD-DEBRIS    
zero occasional abundant 
Conventional 4 10 16 
LBC 12 15 3 
   
               The number of cases with abundant background blood-debris in 
conventional smears is about 16  while only  3 cases in LBC had abundant 
background blood-debris. The number of cases with no background blood-debris 
in LBC is around 12 while 4 cases in conventional smears had  no background 
blood-debris.  
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              In the present study,the number of cases which had poor cytoplasmic and 
nuclear details in conventional FNAC were 3,while the number of cases which 
had poor cytoplasmic and nuclear details in LBC were 5.  
8.Immunocytochemistry on Conventional FNAC . 
Immunocytochemistry was performed on conventional smears of  all 30 
cases.The ER,PR and Her-2/neu status of the cases were analysed.Molecular 
subtyping was done based on this.The number of tumors with ER/PR 
positive,Her-2/neu negative are 9,those with ER/PR positive or negative and Her-
2/neu positive are 10 and there are 11 triple negative tumors. 
Table.19.ER/PR/Her-2/neu status of Carcinoma breast in different grades of 
tumor 
TUMOR 
GRADE 
HR+ 
Her-2/neu- 
HR+/- 
Her-2/neu+ 
TRIPLE 
NEGATIVE 
GRADE I 8 2 - 
GRADE II 1 7 5 
GRADE III - 1 6 
 
9. .Immunocytochemistry on LBC 
Immunocytochemistry was done on LBC smears .It  was noticed that the 
intensity of staining was very poor in  immunocytochemistry done on LBC. The 
cases which were strongly positive in conventional smears were found to be 
negative in LBC smears. So LBC was not found to be as effective as conventional 
FNAC for immunocytochemistry. 
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DISCUSSION 
                                
Breast cancer is now considered as a heterogeneous disease which can be  
divided  into distinct molecular subtypes that has prognostic significance. FNAC 
is a rapid, cheap, atraumatic  procedure that does not require admission of the 
patient in the hospital. This method is found to have good accuracy and 
sensitivity, and is also a relatively simple procedure to procure tumor cells for 
ancillary studies, such as prognostic and predictive biomarkers. 
In the present study, the cytomorphology of breast malignancy in 
conventional FNAC and liquid based preparations stained by H&E Stain are  
compared and analysed.Immunocytochemistry was performed on  conventional 
FNAC smears and molecular subtyping of carcinoma breast was 
done.Immunocytochemistry on LBC was not very useful.In our study,30 cases of  
FNAC proven  malignant lesions of breast were studied. 
Table.20.Number of cases studied in various studies 
Study year No.of cases 
H Sartelet.et.al 2002-2003 103 
Kyoko komatsu.et.al 2006-2007 9 
Minhao.Lv.et.al 2006-2011 102 
Present study 2014-2015 30 
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1. Grading of carcinoma  breast  in FNAC 
In Fine needle aspiration cytology, carcinoma breast can be divided in to 
Grades 1,2 and 3 based on  cell size, arrangement, pleomorphism, nuclear 
membrane, nuclear chromatin and nucleoli. In the present study, there were 10 
cases of Grade 1 tumors,13 cases of grade 2 tumors and 7 cases of grade 3 tumors. 
According to a study by Ahmed Wani.et.al on 110 cases of  breast malignancy 
which was graded on  FNAC by Robinson’s method,25.45%  cases were grade I 
tumors,41.81 % cases were grade II and 32.72% were grade III .In the present 
study,33.3 % cases were grade I,43.3% cases were grade II and  23.3% cases were 
grade III. 
Table.21.Comparison of grading of carcinoma breast with other study 
Study Grade1 Grade2 Grade3 
Ahmed Wani.et.al 25.45% 41.81% 32.72% 
Present study 33.3% 43.3% 23.3% 
 
2.Cytomorphology of breast malignancy in Conventional FNAC and  Liquid-
Based Cytology  
The cytomorphology of  breast malignancy in conventional smears and 
liquid based cytology was compared   using  a semiquantitative  system which 
analysed cellularity, background blood and cell debris, presence of cells in 
monolayers, cell architecture , and  nuclear/cytoplasmic details.  
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A.CELLULARITY 
Table.22.Comparison of adequate cellularity in FNAC and LBC 
Study Adequate/good cellularity 
(conventional FNAC) 
Adequate/good cellularity 
(LBC) 
Ryu.et.al 68.3% 76.7% 
Present study 76.7% 86.7% 
 
The percentage of cases which had adequate/good cellularity in 
conventional FNAC was around 76.6 % while that in LBC was  86.6% .The 
number of cases which had poor cellularity in conventional FNAC is 7 while the 
number of cases with poor cellularity in LBC is around 4. In the present study, the 
p value found using Mcnemar test is around  0.508. Thus, the cellularity in LBC 
was found to be superior  as compared to that in conventional smears. A study by 
Ryu.et.al showed that the number of cases with adequate to good cellularity in 
conventional FNAC was around 68.3%,while that in LBC was 76.7%.The present 
study shows better yield of cellularity in conventional as well as Liquid based 
cytology as compared to the study by  Ryu.et.al. A study by Michael. C.W et.al 130 
also showed that the cellularity in LBC was found to be slightly superior as 
compared to that in conventional smears. Another study by Daskalopoulou.et.al 
also showed that there is great increase in cellularity in LBC aspirates of breast. 
Also,the percentage of cases with poor cellularity in conventional smears was 
found to be 23.3%,in LBC it was 13.3% and when both the methods were 
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combined,it reduced to 3.3%.Thus,if both the methods are used together,the 
cellular yield is much higher. 
B.BACKGROUND BLOOD DEBRIS                          
In the present study, the percentage  of cases with abundant  background 
blood debris  in conventional FNAC was 53.3% and that in LBC was 10%.The p 
value found by Mcnemar test is 1.Thus it is inferred that LBC is better than 
conventional FNAC with less amount of back ground material. In a similar study 
by Ryu.et.al the percentage of cases with background debris in conventional 
FNAC was  68.3%,while that in LBC was 26.7%. Other studies by Michael.C.W 
et.al 130 and   Leung.C.S et.al131 also showed that background is clear in LBC. 
However, there is loss of extracellular material such as mucus and stromal 
fragments in LBC which may be disadvantageous because it results in loss of 
informative background.Thus,LBC is superior to conventional smears with 
respect to clean background. 
C.MONOLAYERS 
The present study shows that the percentage of cases with good 
monolayering in conventional FNAC is 33.3% while that  in LBC is 50%.The 
Mcnemar test shows that  the p value is around  0.307.Thus the study shows that 
LBC smears has more monolayering than conventional smears.  A study by  
Gerhard.et.al also showed that the LBC smears had less overlapping and more 
monolayering than conventional smears. 
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D.CELL ARCHITECTURE                                               
In the present study, the number of cases with non-recognised architecture 
in conventional FNAC are 4(13.3%), while the number of cases with non-
recognised architecture in LBC are 7(23.3%). The p value by Mc nemar test was 
found to be 0.210.  This is analogous to the study conducted by Michael CW.et.al 
and Feoli.F.et.al  which also showed that cellular aggregates are fragmented, 
shortened and less distinct in LBC preparations, resulting in smaller clusters and 
cellular dissociation which leads to poor preservation of cell architecture in LBC 
as compared to that in conventional FNAC. 
E.  CYTOPLASMIC AND NUCLEAR   DETAILS 
In the present study 10% of  the smears in conventional FNAC  showed 
poor  cytoplasmic and nuclear   details while 16.6% of smears in LBC showed 
poor  cytoplasmic and nuclear  details. The  p value by Mcnemar test was found to 
be 0.727. This is analogous to the study done by Simsir.A.et.al  which showed 
that cells in LBC are more rounded and smaller than the flattened cells of  
conventional smear  because the fixative used in LBC is a liquid medium. 
According to Reyes N.et.al  cells in LBC are poorly preserved and nuclei are 
swollen. However, in a study done by  Dey P, it was shown that in LBC the cells 
are better-preserved  with enhanced nuclear detail. A study by Biscotti.C.V.et.al 
also showed that there is better-preservation of cells with enhanced  nuclear detail, 
including a well-defined, usually more pronounced, nucleoli  in LBC.132 
Myoepithelial cells are inconspicuous in LBC smears.     
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Thus, the present study shows that LBC is superior to conventional FNAC 
in terms of cellularity, clean background and monolayers  while the cytoplasmic 
and nuclear details in LBC are not as well preserved as in conventional 
smears.The present study points out that although the conventional FNAC and 
LBC have their own advantages and shortcomings, they have comparable 
diagnostic accuracy and a combination of these methods can be practiced to 
achieve a higher diagnostic rate. 
This was analogous to study conducted by Dey P et al.  which  suggested  
that LBP and CS have comparable diagnostic accuracy in the evaluation of breast 
FNABs. Another study by Bédard YC et al.  which analyzed 7464 breast FNABs 
over a 4-year period, comparing CS with LBP also found that  there was no 
significant difference in diagnostic accuracy. 
IMMUNOCYTOCHEMISTRY IN FNAC AND LBC 
In the present study it was found that the number of tumors with ER/PR 
positive,Her-2/neu negative are 9,those with ER/PR positive or negative and Her-
2/neu positive are 10 and there are 11 triple negative tumors. Of the 10 Grade I 
tumors, 8 cases are HR+/Her-2/neu negative and 2 cases are HR+/- and Her-2/neu 
positive. Of the 13 Grade II tumors,1 tumor was HR+/Her-2/neu negative,7 
tumors were HR+/-,Her-2/neu positive and 5 tumors were triple negative. In 
Grade III tumors,1 tumor was HR+/- and Her-2/neu positive and 6 tumors were 
triple negative. Thus the study shows that majority of Grade I tumors are ER/PR+ 
and Her-2/neu negative, while majority of Grade II tumors were either Her-2/neu 
positive or triple negative and most of the Grade III tumors were triple 
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negative.Thus the prognosis of tumors based on grading correlates with the 
prognosis determined by expression of hormone receptors and Her-2/neu. 
A study by Maynard et al., 1978 and Hilf et al., 1980 also showed that 
tumors which are ER and PR positive tend to be better differentiated and are 
likely to have  better prognosis..A study by  Slamon et al.,1987 and  Tsuda et 
al.,1991 also showed that Her-2/neu  positive tumors are commonly found to have 
a poor histologic grade. 
Neoadjuvant chemotherapy or preoperative systemic therapy is useful in 
patients with operable breast cancer. Neoadjuvant chemotherapy increases the 
scope for breast conserving surgery .It also helps to achieve a pathological 
complete response (pCR; i.e. absence of malignant cells at tumor site.) and 
thereby increased disease free period and overall survival. 
The evaluation of hormone receptors and Her-2/neu status  in FNAC 
smears has largely helped to predict the response to neoadjuvant therapy and 
thereby plan the management protocol for the individual patient. 
However, immunocytochemistry on LBC smears were found to be negative 
in all the cases which were strongly positive in conventional smears. The intensity 
of staining was very poor. The cause for the failure of the procedure is to be 
investigated and further standardisation of the procedure is essential. Thus, in the 
present study immunocytochemistry on LBC is found to be not as effective as in 
conventional smears.                                          
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SUMMARY 
 
 This study includes a total of 30  FNAC proven cases of  carcinoma breast. 
 The cellularity in Liquid based cytology is found to be higher than that in 
conventional FNAC. 
 Combined use of Liquid based cytology and conventional FNAC has better 
diagnostic value in carcinoma breast. 
 The background blood debris is lower in Liquid based cytology than that in 
conventional smears. 
 Monolayering of cells is more common in Liquid based cytology. 
 The cytoplasmic and nuclear details is better preserved in conventional 
FNAC than in Liquid based cytology. 
 In LBC,there are smaller clusters of cells and cellular dissociation is 
present. 
 .Immunocytochemistry can be done on conventional  FNAC smears and 
thereby  subtyping of breast cancer is possible pre-operatively thereby  
judicious planning of neo-adjuvant chemotherapy/hormone therapy as well 
as assessment of prognosis of the tumor  is possible during the pre-
operative period itself.  
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CONCLUSION 
                                          
In our study, it is concluded that although FNAC and LBC has  it’s own 
merits and demerits , they have comparable diagnostic accuracy and the use of 
combination of these methods has superior value in diagnosing breast malignancy 
than either of them alone. Immunocytochemistry on conventional FNAC can 
serve as a reliable tool in the sub typing  of breast malignancy. This helps in 
efficient planning of neo-adjuvant chemotherapy during the pre-operative period 
and has definite prognostic value.  However,  in this study Liquid based cytology 
was found to be not as effective as conventional FNAC in determining the 
prognostic/predictive factors of carcinoma breast. 
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 ANNEXURE-1 
CASE PROFORMA 
 
Case number   : 
Name     : 
Age     : 
Sex    : 
HPE number    : 
IP number    : 
Clinical history   : 
Family history 
Risk factors, if any   : 
Clinical diagnosis   : 
Imaging    : 
Previous FNAC 
 
 
 
 
 
 
 
 
 ANNEXURE-II 
WHO HISTOLOGICAL CLASSIFICATION OF TUMORS OF BREAST 
Epithelial tumors 
Invasive ductal carcinoma,not otherwise specified 
¾ Mixed type carcinoma 
¾ Pleomorphic carcinoma 
¾ Carcinoma with osteoclast like giant cells 
¾ Carcinoma with choriocarcinomatous features 
¾ Carcinoma with melanotic features 
Invasive lobular carcinoma 
Tubular carcinoma 
Invasive cribriform carcinoma 
Medullary carcinoma 
Mucinous carcinoma and other tumors with abundant mucin 
¾ Mucinous carcinoma 
¾ Cystadenocarcinoma and columnar cell mucinous carcinoma 
¾ Signet ring carcinoma 
Neuroendocrine tumors 
¾ Solid neuroendocrine carcinoma 
¾ Atypical carcinoid tumor 
¾ Small cell/oat cell carcinoma 
¾ Large cell neuroendocrine carcinoma 
 
 Invasive papillary carcinoma 
Invasive micropapillary carcinoma 
Apocrine carcinoma 
Metaplastic carcinoma 
¾ Pure epithelial metaplastic carcinoma 
¾ Squamous cell carcinoma 
¾ Adeno carcinoma with spindle cell metaplasia 
¾ Adenosquamous carcinoma 
¾ Mucoepidermoid carcinoma 
¾ Mixed epithelial/mesenchymal metaplastic carcinoma 
Lipid rich carcinoma 
Secretory carcinoma 
Oncocytic carcinoma 
Adenoid cystic carcinoma 
Acinic cell carcinoma 
Glycogen rich clear cell carcinoma 
Sebaceous carcinoma 
Inflammatory carcinoma 
Lobular neoplasia 
¾ Lobular carcinoma in situ 
Intraductal proliferative lesions 
¾ Usual ductal hyperplasia 
¾ Flat epithelial atypia 
 ¾ Atypical ductal hyperplasia 
¾ Ductal carcinoma on situ 
Microinvasive carcinoma 
Intraductal papillary neoplasm 
¾ Central papilloma 
¾ Peripheral papilloma 
¾ Atypical papilloma 
¾ Intraductal papillary carcinoma 
¾ Intracystic papillary carcinoma 
Adenosis including variants 
¾ Sclerosing Adenosis 
¾ Apocrine Adenosis 
¾ Blunt duct Adenosis 
¾ Microglandular Adenosis 
¾ Adenomyoepithelial Adenosis 
Radial scar/complex sclerosing lesion 
Adenomas 
¾ Tubular Adenoma 
¾ Lactating Adenoma 
¾ Apocrine Adenoma 
¾ Pleomorphic Adenoma 
¾ Ductal Adenoma 
 
 Myoepithelial lesions 
Myoepitheliosis 
Adenomyoepithelial adenosis 
Adenomyoepithelioma 
Malignant myoepithelioma 
Mesenchymal tumors 
Hemangioma 
Angiomatosis 
Hemangiopericytoma 
Pseudoangiomatous stromal hyperplasia 
Myofibroblastoma 
Fibromatosis 
Inflammatory myofibroblastic tumor 
Lipoma 
Angiolipoma 
Granular cell tumor 
Neurofibroma 
Schwannoma 
Angiosarcoma 
Liposarcoma 
Rhabdomyosarcoma 
Osteosarcoma 
Leiomyoma 
 Leiomyosarcoma 
Fibroepithelial tumors 
Fibroadenoma 
Phyllodes tumor 
¾ Benign 
¾ Borderline 
¾ Malignant 
Periductal stromal sarcoma,low grade 
Mammary hamartoma 
Tumors of the nipple 
Nipple adenoma 
Syringomatous adenoma 
Pagets disease of nipple 
Malignant lymphoma 
Diffuse large B cell lymphoma 
Burkitt’s lymphoma 
Extranodal marginal zone B Cell lymphoma 
Follicular lymphoma 
Metastatic tumors 
Tumors of the male breast 
Gynaecomastia , Carcinoma :invasive, insitu 
 
 
 ANNEXURE-III 
ஆராvசி தகவ தா 
 
தி¯ெநேவலி அர ெபா¢ ம¯{¢வமைனt மாபக கy­ட} வ¯ 
ேநாயாளக¶t மாபக ©² ேநா உளதா எ}பைத கzடறி­ 
நவ ன ப¾ேசாதைன பறிய ஆராvசி நைடெப² வ¯கிற¢. 
மாபக கy­ட} வ¯ ேநாயாளக¶t மாபக ©² ேநா 
உளதா எ}பைத கzடறி­ நவ ன ப¾ேசாதைன எ|த அளவ 
பயனளt எ}பைத அறி|¢ ெகாவேத இ|த ஆராvசிய} 
ேநாtகமா. 
நuக¶ இ|த ஆராvசிய பuேகக நாuக வ¯©கிேறா. 
«ºகைள அல¢ க¯{¢tகைள ெவளய ேபாேதா அல¢ 
ஆராசிய} ேபாேதா தuகள¢ ெபயைரேயா அல¢ 
அைடயாளuகைளேயா ெவளயடமாyேடா எ}பைத­ ெத¾வ{¢ 
ெகாகிேறா. 
இ|த ஆராvசிய பuேகப¢ தuக¶ைடய வ¯~ப{தி} ேப¾ தா} 
இ¯tகிற¢ ேம´ நuக எ|ேநர« இ|த ஆராvசியலி¯|¢ 
ப}வாuகலா எ}பைத­ ெத¾வ{¢tெகாகிேறா. 
இ|த சிற~© ப¾ேசாதைனகள} «ºகைள ஆராvசிய} ேபாேதா 
அல¢ ஆராvசிய} «வேலா தuக¶t அறிவ~ேபா 
எ}பைத­ ெத¾வ{¢t ெகாகிேறா. 
 
 
 
ஆராvசியாள ைகெயா~ப    பuேகபாள ைகெயா~ப 
ேததி: 
 
 ஆராvசி ஒ~©த கத 
 
ஆராvசி தைல~©:  மாபக கy­ட} வ¯ ேநாயாளக¶t 
மாபக ©² ேநா உளதா எ}பைத 
கzடறி­ நவ ன ப¾ேசாதைன பறிய 
ஆராvசி.  
ெபய:   
வய¢: 
பா: 
ேததி: 
உேநாயாள எz: 
ஆராvசி ேசtைக எz: 
இ|த ஆராvசிய} வவரuக¶ அத} ேநாtகuக¶ «¸ைமயாக 
எனt ெதளவாக வளtக~பyட¢. எனt வளtக~பyட வஷயuகைள 
நா} ©¾|¢ ெகாz என¢ சமத{ைத ெத¾வtகிேற}. 
இத ேதைவயான ப¾ேசாதைனக¶t நா} மனமார சமதிtகிேற}. 
 
 
 
ைகெயா~ப 
 
 
 
 
 
 ANNEXURE-IV 
KEY TO MASTER CHART 
1. MENOPAUSE-    
                           YES-ATTAINED MENOPAUSE 
                               NO-NOT ATTAINED MENOPAUSE   
2. SKIN INVOLVEMENT 
                                          YES-PRESENT 
                                          NO-ABSENT 
3. AXILLARY NODE INVOLVEMENT 
                                          YES-PRESENT 
                                           NO-ABSENT 
4. GRADING 
                                        1-GRADE 1 
                                        2-GRADE 2 
                                        3-GRADE 3 
5. CELLULARITY 
                               1-POOR 
                              2-ADEQUATE 
                               3-GOOD 
6. BACK GROUND BLOOD DEBRIS 
                                    1-ZERO 
                                    2-OCCASIONAL 
                                    3-ABUNDANT  
 7. CELL ARCHITECTURE 
                       NR-NOT RECOGNISED 
                       MR-MODERATELY RECOGNISED 
WR-WELL RECOGNISED 
8. IMMUNOCYTOCHEMISTRY 
NEG-NEGATIVE 
                       POSITIVE-POSITIVE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GRADIN
G OF 
LESION
S. 
N
O
NAME PATH NO IP NO AGE SEX
M
E
N
O
P
A
U
S
E
T
U
M
O
R
 
S
I
Z
E
(
c
m
)
S
K
I
N
 
I
N
V
O
L
V
E
M
E
N
T
A
X
I
L
L
A
R
Y
 
N
O
D
E
 
FNAC FNAC LBC FNAC LBC FNAC LBC FNAC LBC FNAC LBC ER STATUS
PR 
STATUS
HER2 
/neu
ER 
STATUS PR 
Her-
2/neu
1 PETCHIYAMMAL F‐3696/14 217963 55 F Y 3 NO NO 2 2 1 2 2 absent occasional NR MR good poor NEG NEG NEG NEG NEG NEG
2 PACKIYATHAI F‐1829/15  10037 50 F N 3.5 NO YES 3 2 1 1 1 occasional absent MR NR poor good NEG POSITIVEPOPOSITIVE NEG NEG NEG
3 ANNAL SELVI F‐3905/15 69816 65 F Y 5 NO YES 2 1 2 3 2 occasional occasional MR MR good excellent POSITIVE NEG POSITIVE NEG NEG NEG
4 VALLIAMMAL F‐3988/14 69884 65 F Y 7 NO YES 3 1 2 2 2 absent good NR MR good good NEG NEG NEG NEG NEG NEG
5 ANTHONYAMMAL F‐3947/157 71315 60 F Y 5 YES YES 1 1 2 3 1 occasional occasional WR WR good good POSITIVEN NEG NEG NEG NEG NEG
6 MARIAMMAL F‐3900/14 241066 40 F N 4 NO NO 1 1 1 3 1 good good WR MR excellent good NEG POSITIVE NEG NEG NEG NEG
7 PUTHIYAL F‐18/15 72956 65 F Y 8 YES YES 3 2 2 1 1 good occasional MR WR good poor NEG NEG NEG NEG NEG NEG
8 THANGAMMAL F‐147/15 13711 70 F Y 6 NO NO 2 2 3 2 3 occasional good WR WR excellent good POSITIVE POSITIVE NEG NEG NEG NEG
9 ANNAL F‐155/15 12637 62 F Y 5 YES YES 2 2 3 3 1 good occasional MR MR good good NEG NEG POSITIVE NEG NEG NEG
10 MARIAMMAL F‐163/15 4332 40 F N 5 YES NO 2 2 3 3 1 occasional good WR MR poor excellent POSITIVE NEG POSITIVE NEG NEG NEG
11 SANTHI F‐58/15 1013 36 F N 3.5 NO NO 1 2 3 3 2 absent absent MR NR good good POSITIVE POSITIVE NEG NEG NEG NEG
12 SHYAMALA F‐13/15 4025/15 67 F Y 6 YES YES 1 2 3 1 1 good good WR NR good excellent POSITIVE NNEG NEG NEG NEG NEG
13 THAMARAISELVI F‐228/15 19005 48 F N 5 NO YES 2 2 2 3 1 occasional good MR MR excellent good POSITIVE NEG            POSITIVE NEG NEG NEG
14 CHELLAMMAL F‐185/15 4653 63 F Y 4 NO YES 3 2 1 3 2 good occasional WR MR good good NEG NEG NEG NEG NEG NEG
15 SANTHANALAKSHMI F‐349/15 24864 63 F Y 4.5 NO YES 3 2 2 2 1 occasional good MR MR good excellent NEG NEG NEG NEG NEG NEG
16 NATCHIYAR F‐4083/14 72497 60 F Y 6 NO NO 2 1 2 3 2 good absent NR NR good good NEG NEG NEG NEG NEG NEG
17 SUBBUKUTTI F‐435/15 950 45 F N 5 NO NO 1 2 2 2 1 good occasional WR WR good poor NEG NEG POSITIVE NEG NEG NEG
18 SUDHA F‐528/15 10229 48 F N 5.5 NO YES 2 2 3 3 2 absent good MR NR poor good NEG            NEGATIVE  NEG NEG NEG NEG
19 ARUMUGAM F‐510/15 25765 55 F Y 6 YES YES 1 3 2 2 3 good occasional WR NR excellent good POSITIVE P POSITIVE NEG NEG NEG NEG
20 MALLIKA F‐574/15 69785 60 F Y 5.5 NO NO 2 2 2 3 2 occasional good WR MR good poor POSITIVE NEGATIVE  POSITIVE NEG NEG NEG
21 CHANDRA F‐1098/15 64652 55 F Y 4.5 YES NO 3 2 2 3 2 absent good WR MR excellent good NEG            NEG            NEG NEG NEG NEG
22 PAPPA F‐1102/15 64835 55 F Y 4 NO YES 1 2 2 3 2 good occasional MR  MR good good POSITIVE POSITIVE NEG NEG NEG NEG
23 IYYAMMAL F‐1187/15 21947 45 F N 5.5 NO NO 2 2 2 3 2 occasional absent WR MR good excellent NEG            NEG NEG NEG NEG NEG
24 ANANDHI F‐1820/15 96795 49 F N 4 NO YES 2 2 2 2 2 absent good MR MR good good NEG NEG POSITIVE NEG NEG NEG
25 CHELLATHAI F‐1971/15 107115 62 F Y 5 YES NO 2 3 2 2 2 occasional good WR WR excellent good NEG            NEG            POSITIVE NEG NEG NEG
26 SEETHA F‐3805/14 233422 40 F N 3.5 NO NO 1 1 2 3 1 absent occasional MR WR good excellent POSITIVE NNEG POSITIVE NEG NEG NEG
27 CHELLAMMAL F‐601/15 38006 51 F Y 3 NO NO 1 1 2 1 3 good good NR NR excellent poor POSITIVE POSITIVE NEG NEG NEG NEG
28 CHIDAMBARAM F‐53/15 4711 75 F Y 8 NO YES 3 2 2 3 1 occasional good WR WR good good NEG NEG NEG NEG NEG NEG
29 SALIKA BEEVI F‐503/15 34558 50 F Y 6 NO NO 2 2 2 2 2 absent occasional MR WR good excellent NEG NEG NEG NEG NEG NEG
30 VIJAYALAKSHMI F‐535/15 101514 45 F Y 4.5 NO NO 1 2 2 2 2 occasional good MR MR good good POSITIVE NEG NEG NEG NEG NEG
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